J Neurogastroenterol Motil.  2014 Apr;20(2):141-151.

Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation

• Eswaran S
• Guentner A
• Chey WD

Abstract

Irritable bowel syndrome with constipation and chronic functional constipation are common digestive disorders that negatively impact quality of life and account for billions of dollars in health care costs. Related to the heterogeneity of pathogenesis that underlie these disorders and the failure of symptoms to reliably predict underlying pathophysiology, traditional therapies provide relief to only a subset of affected individuals. The evidence surrounding new and emerging pharmacologic treatments, which include both luminally and systemically acting drugs, is discussed here. These include agents such as lubiprostone, bile acid modulations, guanylate cyclase-C receptor agonists, serotonin receptor modulators and herbal therapies.

Keyword

Bile acid and salts; Constipation; Irritable bowel syndrome; Laxatives; Therapeutics

MeSH Terms

Bile
Constipation*
Health Care Costs
Irritable Bowel Syndrome*
Laxatives
Population Characteristics
Quality of Life
Serotonin Receptor Agonists
Lubiprostone
Laxatives
Serotonin Receptor Agonists